CFU

Canadian Freelance Union announces massive drive to organize freelancers; interpreters and translators form first unit

Retrieved on: 
Friday, May 3, 2024
ITU, Arabic, Dignity, Health, Insurance, Partnership, Workplace, Conference, Human, Growth, CFU, Interpretation, Language interpretation, Nursing

TORONTO, May 3, 2024 /CNW/ - Canada's main voice for freelance workers is thrilled to announce an organizing drive that will expand the membership of the Canadian Freelance Union beyond communications workers.

Key Points: 
  • TORONTO, May 3, 2024 /CNW/ - Canada's main voice for freelance workers is thrilled to announce an organizing drive that will expand the membership of the Canadian Freelance Union beyond communications workers.
  • The first group to join en masse are interpreters and translators who work in provincial courtrooms, health centres, and in the community, members of the Interpreters and Translators Unit (ITU).
  • However, alongside this growth, freelance workers face numerous challenges, including precarious working conditions, lack of benefits, and insufficient protections.
  • Recognizing the importance of solidarity and collective action, freelance interpretation and translation workers have united under the banner of Interpreters and Translators Unit - Canadian Freelance Union (ITU-CFU) to address these issues head-on.

USDA Finalizes Policy to Protect Consumers from Salmonella in Raw Breaded Stuffed Chicken Products

Retrieved on: 
Friday, April 26, 2024
Poultry, Federal Register, Sale, Public, Food safety, Risk, Policy, Food, CDC, Disease, Animal, Salmonellosis, USDA, Guideline, Farmer, Agriculture, CFU, Science, STEC, Escherichia coli, Register, Infection, FSIS, Poultry farming

“This final determination marks the first time that Salmonella is being declared an adulterant in a class of raw poultry products.

Key Points: 
  • “This final determination marks the first time that Salmonella is being declared an adulterant in a class of raw poultry products.
  • If the chicken component in these products does not meet this standard, the product lot represented by the sampled component would not be permitted to be used to produce the final raw breaded stuffed chicken products.
  • In determining that Salmonella is an adulterant in raw breaded stuffed chicken products, FSIS considered the best available science and data using similar criteria as in its 1994, 1999, and 2011 E. coli policymaking.
  • Raw breaded stuffed chicken products are pre-browned and may appear cooked, but the chicken is raw.

Sports Diplomacy: Uzbekistan Ambassador Invites UK and Uzbek Cricketers for Talks

Retrieved on: 
Monday, January 22, 2024
Woman, University, Bat, CFU, ICC, University of Warwick, Athlete, CIS, Government, Sport, Growth, Oval, Usmanov, MBA, Fergana Valley, Aptitude, Interest, International Cricket Council, Atmosphere, Century, Sports equipment

LONDON, Jan. 22, 2024 /PRNewswire/ -- In what has become his trademark style, recently appointed Uzbekistan Ambassador Ravshan Usmanov today continued his high-energy round of get-acquainted meetings with key people in unusual fields by bringing together cricketers from the UK and from his homeland to discuss how their sport serves the bilateral relationship.

Key Points: 
  • But he has also been inviting spokesmen for more surprising corners of society to discuss their current relationships with Uzbekistan.
  • A businessman, with an MBA from Warwick University, Mr. Mihliev says cricket is the fastest growing sport in Uzbekistan.
  • "We have high expectations of the UK helping Uzbek cricket rise quickly to professional levels," he said.
  • Both Mr. Gaffney and Mr. Mihliev paid credit to Sophie Ibbotson, a UK brand ambassador for the Uzbekistan Tourism Committee, for bringing them together.

Sports Diplomacy: Uzbekistan Ambassador Invites UK and Uzbek Cricketers for Talks

Retrieved on: 
Monday, January 22, 2024
Woman, University, Bat, CFU, ICC, University of Warwick, Athlete, CIS, Government, Sport, Growth, Oval, Usmanov, MBA, Fergana Valley, Aptitude, Interest, International Cricket Council, Atmosphere, Century, Sports equipment

LONDON, Jan. 22, 2024 /PRNewswire/ -- In what has become his trademark style, recently appointed Uzbekistan Ambassador Ravshan Usmanov today continued his high-energy round of get-acquainted meetings with key people in unusual fields by bringing together cricketers from the UK and from his homeland to discuss how their sport serves the bilateral relationship.

Key Points: 
  • But he has also been inviting spokesmen for more surprising corners of society to discuss their current relationships with Uzbekistan.
  • A businessman, with an MBA from Warwick University, Mr. Mihliev says cricket is the fastest growing sport in Uzbekistan.
  • "We have high expectations of the UK helping Uzbek cricket rise quickly to professional levels," he said.
  • Both Mr. Gaffney and Mr. Mihliev paid credit to Sophie Ibbotson, a UK brand ambassador for the Uzbekistan Tourism Committee, for bringing them together.

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Retrieved on: 
Wednesday, January 10, 2024
TTD, CFU, USP, Commercial, Sale, Automation, 3D printing

LOWELL, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it expects the commercial launch of the Growth Direct Rapid Sterility application by mid-year 2024.

Key Points: 
  • The Company has developed a novel, proprietary Rapid Sterility application for use with its Growth Direct system.
  • “We are extremely excited about the data and the results we have achieved with our new Growth Direct Rapid Sterility application – this is truly a breakthrough technology,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.
  • In addition, we expect that the Growth Direct Rapid Sterility application will enable faster release of final pharmaceutical product, allowing manufacturers to benefit from faster time to market, less potential waste and reduced inventory and holding costs.
  • Commercial launch of the Growth Direct Rapid Sterility application is expected by mid-year 2024.

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Drug development, Disease, NESS, Safety, NYSE, Policy, Senior, Food, Cystic fibrosis, Plasma protein binding, H.262/MPEG-2 Part 2, Workforce, Sputum, Clinical trial, Mortality, Insurance, Patient, Research, Part, FDA, Pharmacokinetics, Bacteria, Novartis, Conference, Pseudomonas aeruginosa, FEV1, Communication, CFU, Dermatology, Physician, Psoriatic arthritis, Fast Track, Part Two, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.
  • In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential of this promising program.
  • Net loss for the third quarter of 2023 was $7.9 million, compared to $6.8 million for the same period in 2022.
  • Net cash used in operating activities for the nine months ended September 30, 2023, was $15.0 million, compared to $21.9 million for the same period in 2022.

Not Just Yogurt Anymore

Retrieved on: 
Thursday, October 26, 2023
CFU, Meal, Drink, Food court, Novozymes, Snack, Coffee, Cell, Probiotic, Functional food, Bacillus subtilis, Food, Dietary supplement

FRANKLINTON, N.C., Oct. 26, 2023 /PRNewswire/ -- Novozymes is excited to launch ProSilience™ HU58, a probiotic with superior stability and low cost-in-use that may help change the way America eats breakfast (and snacks and other meals).

Key Points: 
  • The probiotic can withstand harsh processing conditions, allowing it to become an ingredient in entirely new food categories – for example, breakfast cereal or coffee.
  • "ProSilience™ HU58 provides the clinically supported digestive and immune benefits that consumers demand," says Stephen Quinn, Novozymes Industry Manager, Functional Foods.
  • The new product is a part of Novozymes' commitment to driving innovation in biosolutions and promoting healthy, sustainable food choices.
  • Easy handling: ProSilience™ HU58 is easy to formulate, easy to incorporate into existing production lines, and supported by Novozymes Technical Service.

ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine

Retrieved on: 
Tuesday, September 5, 2023
Other Health, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Vaccine, Bordetella pertussis, Cold medicine, University Hospital Southampton NHS Foundation Trust, University, Vaccination, Culture, Public, Immunity, Infection, CFU, CDC, Epidemic, Quarantine, Death, Congress, Professor, CFU-GEMM, Clutch (eggs), United Kingdom, Iliad, Immunization, University of Oxford, Safety, Disease, MD

ILiAD Biotechnologies reported today that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study.

Key Points: 
  • ILiAD Biotechnologies reported today that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study.
  • The CHAMPION-1 Phase 2b Human Challenge study is a randomized, double-blind, placebo-controlled study of BPZE1 vaccine in healthy adults.
  • The study has a primary objective to demonstrate that prior immunization with BPZE1 protects against colonization as evidenced by negative B. pertussis culture following virulent B. pertussis challenge 2–4 months after vaccination.
  • As a result, the preparation method of the B. pertussis challenge dose was modified to achieve the per-protocol adequate inoculum of B. pertussis challenge as specified in the original study protocol.

Peloton Kicks Off College Strategy Engaging Students, Athletes, and Alumni

Retrieved on: 
Tuesday, August 22, 2023
University, Gen, Magic, Social media, CFU, Generation Z, Athlete, Student, Medical Academy named after S.I. Georgievsky of Vernadsky CFU, Peloton Interactive, Bicycle, Health, Exercise, Sport, Nursing

Finally, Peloton will also partner to create opportunities for alumni and fans to experience related benefits.

Key Points: 
  • Finally, Peloton will also partner to create opportunities for alumni and fans to experience related benefits.
  • Additionally, Peloton offers K-12 US teachers, college educators, and administrators access to discounted offers for its world class connected fitness portfolio.
  • Peloton is excited to be a part of their journey," said Dion Camp Sanders, Peloton Chief Emerging Business Officer.
  • "By merging our expertise, athletic fandom, and college communities at-large, we aim to support and inspire students, alumni, and college communities to achieve their fitness ambitions."

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 9, 2023
Insurance, Communication, CFA, Cystic fibrosis, Data analysis, Patient, Cystic Fibrosis Foundation, Disease, NYSE, PIPE, Policy, Pharmacokinetics, CFU, Pseudomonas aeruginosa, Corporation, Bacteria, Treasurer, FDA, CF, Conference, Safety, International, Professional corporation, ECFC, Psoriatic arthritis, Mortality, Research, Therapy, FEV1, Sputum, Workforce, Drug development, Clinical trial, Urinary tract infection, Fast Track, Part, Plasma protein binding, NESS, Phage therapy, Poster, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Biogen, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.
  • “Our BX004 clinical program in cystic fibrosis (“CF”) continues to build significant momentum,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Net loss for the second quarter of 2023 was $6.4 million, compared to $7.5 million for the same period in 2022.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter of 2023.